Some of the most serious unmet patient needs today are in the field of hematology, and we are committed to breaking barriers through groundbreaking science to significantly improve the health and lives of people with rare blood disorders around the world.
In 2018, we created our Rare Blood Disorders franchise with two strategic acquisitions [Bioverativ and Ablynx] and in-house programs with a goal of addressing unmet needs and fundamentally redefining the management of these rare and often chronic diseases. Inspired by patients and driven by science, we are focused on helping to make a transformative difference in the standard of care for people affected by rare blood disorders around the world.
Hemophilia, a rare genetic blood disorder that impairs the ability of blood to clot, is the cornerstone of our Rare Blood Disorders franchise. Our extended half-life factor replacement therapies for people with hemophilia A and B were the first innovations in hemophilia management in 20 years when launched in 2014 and have since been used to treat over 3,500 people with hemophilia worldwide. We have a steadfast commitment to the hemophilia community and are continuing to explore potential new treatment approaches which could allow patients to live a more active life.
Building on our legacy of innovation for patients with limited treatment options, we launched the first approved treatment for acquired thrombotic thrombocytopenic purpura (aTTP). aTTP is a rare, life-threatening, autoimmune-based blood disorder characterized by extensive clot formation in small blood vessels throughout the body, leading to a very low platelet count, a loss of red blood cells and restricted blood supply to parts of the body.